Deerfield Management Company L.P. Series C Has $264,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Deerfield Management Company L.P. Series C decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 96.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,300 shares of the company’s stock after selling 773,684 shares during the quarter. Deerfield Management Company L.P. Series C’s holdings in Replimune Group were worth $264,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares in the last quarter. Point72 DIFC Ltd bought a new position in Replimune Group during the second quarter worth about $57,000. Diversified Trust Co bought a new position in Replimune Group during the first quarter worth about $94,000. China Universal Asset Management Co. Ltd. grew its stake in Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after acquiring an additional 4,975 shares during the period. Finally, Arizona State Retirement System bought a new stake in shares of Replimune Group in the second quarter worth about $108,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Up 0.3 %

Replimune Group stock opened at $11.16 on Friday. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.14. The company has a fifty day simple moving average of $10.34 and a 200 day simple moving average of $8.51. The company has a market cap of $762.45 million, a P/E ratio of -3.44 and a beta of 1.22.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.10. Research analysts anticipate that Replimune Group, Inc. will post -3.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on REPL shares. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a report on Thursday, June 6th. Roth Mkm initiated coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Barclays increased their target price on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $16.80.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at $1,028,760.26. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 20.60% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.